In a significant regulatory decision, the U.S. Food and Drug Administration (FDA) has approved an update to the label for the long-acting contraceptive Depo-Provera (medroxyprogesterone acetate). The change, finalized in December 2025, adds a formal warning about a potential increased risk of developing meningioma, a type of brain tumor. This action follows emerging scientific evidence and marks a pivotal moment for patient awareness and informed choice.
The FDA’s Decision and Evolving Evidence
This label update represents a notable shift. The FDA had previously denied a similar request from the manufacturer, Pfizer, in early 2024, citing that the data at the time was not sufficiently clear. The agency’s recent reversal is directly tied to the publication of key studies that strengthened the link between the contraceptive injection and meningioma risk:
- A March 2024 study in The BMJ reported a fivefold increased risk for meningiomas in users.
- A September 2024 study in JAMA Neurology found a twofold increased risk, noting the greatest risk was for women who began using the injection after age 31 or who used it for four years or more.
This mounting evidence prompted the FDA to require the warning, which applies to both formulations: Depo-Provera CI (intramuscular injection) and Depo-SubQ Provera 104 (subcutaneous injection).
Details of the New Warning
The official prescribing information has been revised with a new section, “5.4 Meningioma.” It states that “cases of meningiomas have been reported following repeated administration of medroxyprogesterone acetate, primarily with long term use.” The label provides clear directives for healthcare providers:
- Monitoring: Patients using Depo-Provera should be monitored for signs and symptoms of meningioma (which can include headaches, vision changes, or seizures, depending on the tumor’s location).
- Discontinuation: The medication must be discontinued if a meningioma is diagnosed.
- Contraindication: Depo-Provera is now contraindicated for patients with an existing meningioma or a history of the condition.
Legal and Medical Context
The regulatory change occurs against a backdrop of significant legal action. According to the article, the United States Judicial Panel on Multidistrict Litigation reports that more than 1,400 lawsuits have been filed against Pfizer. These lawsuits allege that the company knew or should have known about the meningioma risk and failed to adequately warn users.
It is important to note that the meningioma warning joins other established, significant risks associated with Depo-Provera, most notably a boxed warning for loss of bone mineral density. The label explicitly states the drug is not recommended as a long-term (longer than two years) birth control method unless other options are considered inadequate.
Pfizer’s Response
In a statement, Pfizer confirmed it is working with the FDA to update the prescribing information. The company emphasized that “patient safety is Pfizer’s priority” and highlighted its “rigorous and continuous monitoring” of all its medicines. The statement concluded by asserting that the company “stands behind the safety and efficacy of Depo-Provera, which has been used by millions of women worldwide and remains an important treatment option.”
Conclusion
The addition of a meningioma warning to Depo-Provera’s label is a critical development in women’s healthcare. It underscores the essential role of post-market surveillance in identifying long-term drug risks, even for medications used for decades. For current and potential users, this update reinforces the necessity of having detailed discussions with healthcare providers about all contraceptive options, weighing their benefits against potential risks, both new and established, to make fully informed personal health decisions.
